This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chintagumpala, M. Articles by Berg, S. L. Search for Related Content PubMed PubMed Citation Articles by Chintagumpala, M. Articles by Berg, S. L. Social Bookmarking                            What's this?

Phase I and Pharmacokinetic Study of Thalidomide With Carboplatin in Children With Cancer

From the Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine; and The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Stacey Berg, MD, Texas Children's Cancer Center, 6621 Fannin, MC 3-3320, Houston, TX 77030; e-mail: sberg{at}txccc.org

PURPOSE: Tumor growth and metastasis is believed to depend on the tumor's ability to induce neovascularization. Recent studies have indicated that thalidomide inhibits angiogenesis. We performed a phase I and pharmacokinetic study of thalidomide with carboplatin in children with refractory solid tumors.

PATIENTS AND METHODS: Carboplatin was administered as a single intravenous dose once every 21 days at a target area under the concentration-time curve of 6 mg/mL·min. Thalidomide was administered daily by mouth. The initial dose level was 100 mg/m²/d with intrapatient dose escalation to a maximum dose of 300 mg/m²/d. The next cohort of patients started at a dose of 300 mg/m²/d, with intrapatient dose escalation to a maximum dose of 500 mg/m²/d. Standard response and adverse event criteria were used. Serial blood samples for thalidomide pharmacokinetics studies were obtained after the first dose.

RESULTS: Twenty-two patients received 56 cycles of therapy. The maximum tolerated thalidomide dose was 400 mg/m²/d. The dose-limiting toxicity was somnolence. There were no objective responses. Thalidomide's apparent clearance was 55 ± 16 mL/min/m² and the terminal half-life was 5.9 ± 2.8 hours. There was no evidence of dose-dependent pharmacokinetics in the narrow range studied.

CONCLUSION: Thalidomide at a dose of 400 mg/m²/d can be safely administered to children with solid tumors in combination with carboplatin. Somnolence is the major toxicity. In addition, we have characterized the pharmacokinetic behavior of thalidomide in children. This study can serve as the basis for future investigation of thalidomide as an anticancer agent in children.

Supported in part by the National Institutes of Health General Clinical Research Center grant M01 RR00188.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?